XNASEQ
Market cap22mUSD
Jan 17, Last price
0.64USD
1D
-8.00%
1Q
-43.02%
IPO
-95.40%
Name
Equillium Inc
Chart & Performance
P/E
—
P/S
0.63
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
23.29%
Rev. gr., 5y
%
Revenues
36m
+128.97%
Net income
-13m
L-87.62%
CFO
-22m
L+149.43%
Earnings
May 22, 2025
Profile
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
IPO date
Oct 12, 2018
Employees
47
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 36,084 128.97% | 15,759 | |||||
Cost of revenue | 50,732 | 54,904 | |||||
Unusual Expense (Income) | |||||||
NOPBT | (14,648) | (39,145) | |||||
NOPBT Margin | |||||||
Operating Taxes | 580 | 45,279 | |||||
Tax Rate | |||||||
NOPAT | (15,228) | (84,424) | |||||
Net income | (13,335) -87.62% | (107,707) 176.31% | |||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | (95) | 214 | |||||
BB yield | 0.38% | -0.60% | |||||
| Debt | |||||||
Debt current | 880 | 6,122 | |||||
Long-term debt | 1,208 | 5,295 | |||||
Deferred revenue | 10,378 | ||||||
Other long-term liabilities | 4,063 | ||||||
Net debt | (38,778) | (59,606) | |||||
| Cash flow | |||||||
Cash from operating activities | (21,783) | (8,733) | |||||
CAPEX | (50) | (279) | |||||
Cash from investing activities | (4,762) | 18,684 | |||||
Cash from financing activities | (9,228) | (1,215) | |||||
FCF | (15,148) | (83,970) | |||||
| Balance | |||||||
Cash | 40,866 | 71,023 | |||||
Long term investments | |||||||
Excess cash | 39,062 | 70,235 | |||||
Stockholders' equity | (185,597) | (172,326) | |||||
Invested Capital | 209,434 | 228,894 | |||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 34,726 | 33,728 | |||||
Price | 0.72 -31.79% | 1.06 -71.88% | |||||
Market cap | 25,107 -29.77% | 35,752 -67.08% | |||||
EV | (13,671) | (23,854) | |||||
EBITDA | (14,522) | (39,027) | |||||
EV/EBITDA | 0.94 | 0.61 | |||||
Interest | 491 | 1,053 | |||||
Interest/NOPBT | |||||||